Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 4:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1609–1632 of 16,128 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin Disorder Clear all

Conditions: Breast Cancer, Tumor, Breast, Breast Tumor, Malignant Neoplasm of Breast, Mammary Cancer, Mammary Neoplasm, Mammary Neoplasms, Human, Neoplasm, Breast
Interventions: HTR2 T Cells; Genetic
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2044
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Pain, Fibromyalgia, Osteoarthritis, Knee, Osteoarthritis, Hip, Osteoarthritis, Ankylosing Spondylitis, Rheumatoid Arthritis, Chronic Low-back Pain, Chronic Shoulder Pain
Interventions: No intervention, observational only.; Other
Lead sponsor: Illinois Institute of Technology; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Carcinoma
Interventions: Biospecimen Collection, Questionnaire Administration; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: Not listed
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2034
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Breast Cancer
Interventions: Selene; Device
Lead sponsor: Perimeter Medical Imaging; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 613 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 10
States / cities: Jacksonville, Florida • Tampa, Florida • Meadowbrook, Pennsylvania + 6 more

Conditions: Refractory Solid Tumors, Melanoma
Interventions: IMO-2125; Drug
Lead sponsor: Idera Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 8
States / cities: Scottsdale, Arizona • Tucson, Arizona • San Francisco, California + 5 more

Conditions: Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ, Hot Flashes
Interventions: EMBr Wave, Questionnaire Administration; Device · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions: ganetespib, paclitaxel, trastuzumab, pertuzumab; Drug · Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 2
States / cities: New York, New York

Conditions: Meniscal Tear, Chondromalacia
Interventions: Arthroscopic debridement; Procedure
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 30 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Malignant Melanoma
Interventions: HyperAcute-Melanoma Vaccine; Biological
Lead sponsor: NewLink Genetics Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Chronic Plaque Psoriasis
Interventions: AIN457, Placebo; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 5
States / cities: Santa Monica, California • Louisville, Kentucky • High Point, North Carolina + 2 more

Conditions: Breast Cancer
Interventions: Magnetic Resonance Imaging (MRI), Gadavist; Procedure · Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Female only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Breast Cancer
Interventions: U-13C-glucose; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: New Brunswick, New Jersey

Conditions: Skin Laxity, Wrinkle, Skin Condition
Interventions: Profound Matrix; Device
Lead sponsor: Candela Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 4
States / cities: Jacksonville, Florida • Marlborough, Massachusetts • Fayetteville, North Carolina + 1 more

Conditions: Melasma
Interventions: Revlite Laser System with hydroquinone skin care regimen, Hydroquinone skin care regimen; Device · Other
Lead sponsor: Cynosure, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Urothelial Carcinoma, Head and Neck Cancer, Melanoma, Bladder Urothelial Carcinoma
Interventions: Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cells; Genetic
Lead sponsor: Adaptimmune; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 8
States / cities: Boston, Massachusetts • St Louis, Missouri • Buffalo, New York + 4 more

Conditions: Breast Cancer
Interventions: Interstitial Implant Brachytherapy; Radiation
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acne Vulgaris
Interventions: Botulinum Neurotoxin Type A, Bacteriostatic saline; Drug
Lead sponsor: DeNova Research; Other
Eligibility: 18 Years to 50 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Gynecomastia
Interventions: Anastrozole (ARIMIDEX™); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 11 Years to 18 Years · Male only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Onychomycosis
Interventions: Efinaconazole; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 6 Years to 16 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 9
States / cities: Birmingham, Alabama • Fountain Valley, California • Santa Rosa, California + 6 more

Conditions: Breast Cancer
Interventions: Four Conversations; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Onychomycosis
Interventions: terbinafine, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 20
States / cities: Birmingham, Alabama • San Diego, California • Denver, Colorado + 16 more

Conditions: Triple Negative Breast Cancer
Interventions: [18F]FMISO-PET with contrast-enhanced MRI; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Breast Neoplasms, Neoplasms
Interventions: neratinib; Drug
Lead sponsor: Puma Biotechnology, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2018
U.S. locations: 13
States / cities: Aurora, Colorado • Zion, Illinois • Shreveport, Louisiana + 7 more

Conditions: Osteoarthritis, Post-Traumatic Arthritis, Rheumatoid Arthritis
Interventions: Scandinavian Total Ankle Replacement (STAR); Device
Lead sponsor: Link America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2001
U.S. locations: 5
States / cities: Jacksonville, Florida • Iowa City, Iowa • Kansas City, Kansas + 2 more

Search by objective public record fields.

TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer

Chronic Pain, Couples, & Physical Activity

Long Term Followup of Patients Enrolled in MC1137, BEAUTY Study

Wide Field OCT + AI for Positive Margin Rates in Breast Conservation Surgery.

A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors

EMBr Wave for the Reduction of Hot Flashes in Women With a History of Breast Cancer

Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

The ChAMP (Chondral Lesions And Meniscus Procedures) Trial

Vaccine Treatment for Advanced Malignant Melanoma

Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis

Contrast-Enhanced MRI for the Characterization of Ductal Carcinoma in Situ (DCIS)

Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer

Clinical Feasibility Study to Evaluate the Safety and Performance of the Profound Matrix System

A Study of the RevLite Laser System for the Treatment of Refractory Mixed Type Melasma

MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers

Treatment of T1N0 Invasive Breast Carcinoma by Local Excision Implant

Safety and Efficacy of the Use of Botox on Acne

Open Label Arimidex in Gynecomastia

Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis

Four Conversations RCT

Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail

Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI)

Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer

Study of the Scandinavian Total Ankle Replacement (STAR) for the Treatment of Bilateral Degenerative Ankle Disease